---
schema_version: "secwatch.filing_event.v1"
accession: "0001161697-23-000156"
form_type: "8-K"
ticker: "KRMD"
cik: "0000704440"
company_name: "KORU Medical Systems, Inc."
filed_at: "2023-03-08T23:59:59+00:00"
generated_at: "2026-06-18T09:02:17.490848+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# KORU Medical reports 19% revenue growth in 2022, guides 17-20% growth for 2023

## Summary
- Q4 2022 revenue $7.34M (+13.2% YoY); FY2022 revenue $27.9M (+18.8% YoY).
- FY2022 net loss $8.6M ($0.19 loss per share) vs $4.6M loss in 2021.
- Novel Therapies revenue grew 329.8% to $2.5M; Core business grew 11%.
- Cash $17.4M at year-end; 2023 guidance: revenue $32.5-$33.5M (17-20% growth), gross margins 58-60%, cash >$10M.
- Expects 6 new Novel Therapies collaborations and two 510(k) filings in H2 2023.

## SEC filing metadata
- accession: 0001161697-23-000156
- form_type: 8-K
- ticker: KRMD
- cik: 0000704440
- company_name: KORU Medical Systems, Inc.
- filed_at: 2023-03-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/0001161697-23-000156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/form_8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001161697-23-000156
- JSON: https://secwatch.observer/filing/0001161697-23-000156.json
- Plain text: https://secwatch.observer/filing/0001161697-23-000156.txt

## Key facts
- Earnings Releases
  KORU Medical Systems, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $7.3 million, net income Net loss for the fourth quarter of 2022 was $ 2.0 million, EPS $(0.04) per diluted share. Guidance raised.
  - Period: fourth quarter and full year ended December 31, 2022
  - Revenue: $7.3 million
  - Net income: Net loss for the fourth quarter of 2022 was $ 2.0 million
  - EPS: $(0.04) per diluted share
  - Guidance: raised
  - Result: reported results
  source text: fourth quarter and full year ended December 31, 2022. The Company also issued guidance for the full year 2023. Recent Highlights: ● Fourth quarter net revenue growth of 13% to $7.3 million, marking the fifth consecutive quarter of double-digit growth, and full year net revenue growth of 19% to $27.9 million ● Novel Therapies business finished the year with 14 total
  evidence_url: https://www.sec.gov/Archives/edgar/data/704440/000116169723000156/0001161697-23-000156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.